Connect your AI

Arcus Biosciences RCUS Other Working Capital

Other Working Capital at other companies

Bristol-Myers SquibbBMY

$1.64B+54.5%

IncyteINCY

-$12.77M-141%

ImmunityBio, Inc.IBRX

$16K-93.4%

Nuvalent, Inc.NUVL

-$120K-275%

ExelixisEXEL

$2.02M-57.8%

Kymera TherapeuticsKYMR

-$2.15M-410%

Other financials

Income statement

Revenue$17.0M-39.3%

Operating income-$134.0M-9.8%

Net income-$128.0M-14.3%

EPS (diluted)-$1.02+10.5%

Balance sheet

Cash & equivalents$201.0M+4.7%

Total debt$113.0M+88.3%

Total equity$524.0M-1.3%

Total assets$997.0M-13.8%

Cash flow

Operating cash flow-$138.0M-4.5%

CapEx--100%

Free cash flow-$138.0M-3.8%

Valuation

Market cap$3.54B+226%

Enterprise value$3.46B+275%

P/S15×+7.3×

Profitability

Operating margin-168.6%-52.7pp

Net margin-156.4%-47.5pp

FCF margin-207.2%—

Returns & leverage

Return on equity-70%+8.4pp

Debt / equity0.2×+0.1×

Current ratio4×-1.3×

Where this comes from

Reported directly by Arcus Biosciences in its filing.

Tagged under the XBRL concept us-gaap:OtherOperatingActivitiesCashFlowStatement.

The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcus Biosciences's other working capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Arcus Biosciences's other working capital?: Arcus Biosciences (RCUS) reported other working capital of $1M in Q1 2026.
What does other working capital mean?: Net change in working capital items not separately classified — a residual balancing item.